Jones Trading has upgraded Spyre Therapeutics Inc (SYRE) to a Buy rating from Hold, reflecting a more optimistic outlook on the company's future prospects. The upgrade, effective November 30, 2025, comes as Spyre's current stock price stands at $29.32.
This change in analyst sentiment may indicate improved fundamentals or better-than-expected business performance. Spyre Therapeutics, a clinical-stage biotechnology company based in Waltham, Massachusetts, focuses on developing innovative human enzyme therapeutics for rare and high-burden diseases. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23, with advanced product candidate SPY001 designed for the treatment of inflammatory bowel disease (IBD).
With a market capitalization of $2.1 billion and a trailing twelve months EPS of -4.43, the company is gearing up for its next earnings report on August 3, 2026, where it is expected to post an EPS of -0.61 with zero revenue.
Analyst ratings, such as this latest upgrade, provide valuable insights based on research and financial models. However, they should be considered alongside various factors, including company fundamentals and market conditions. As new information emerges, analyst ratings can shift, reflecting the dynamic nature of the market.
As of December 1, 2025, the consensus among analysts is a Buy rating, with 10 Strong Buy, 8 Buy, and 1 Hold ratings. Recent actions include Deutsche Bank initiating coverage with a Buy rating and BTIG reaffirming its Buy stance, highlighting the growing confidence in Spyre's strategic direction.